Millions of people suffering from Long COVID have struggled to find effective treatments for lingering symptoms such as chronic fatigue, brain fog, and post-nasal drip. Until recently, relief seemed out of reach. Now, a therapy previously available only in Japan is helping patients in the U.S. regain their health. Dr. Robert Groysman, a specialist in Long COVID treatment, has introduced epipharyngeal abrasive therapy (EAT) at his Dallas-based clinic.*

A Simple, Non-Invasive Approach to Healing

Scientists believe these symptoms might be caused by lingering post-viral inflammation, especially in the epipharynx, a part of the throat where the virus first attacks. EAT has been widely used in Japan for a throat condition called chronic epipharyngitis, whose symptoms—fatigue, headaches, and trouble concentrating—are very similar to several of those seen in Long COVID. 

EAT offers a different approach than other Long COVID treatments, however. Rather than simply managing symptoms, EAT targets the underlying causes by reducing immune overactivation and restoring balance between the branches of the autonomic nervous system (ANS). 

This therapy has shown effectiveness in alleviating persistent symptoms such as:

• Brain fog, 
• Chronic fatigue,
• Dizziness, and 
• Postnasal drip. 

Dr. Groysman, a board-certified interventional pain specialist, has witnessed firsthand the benefits of EAT, saying that, “It is a great tool in the Long COVID treatment arsenal.”

How EAT Therapy Works

EAT involves an application of zinc chloride solution to the inflamed tissue, and gentle stimulation of the epipharyngeal region in the nasal and throat areas, directly impacting immune system regulation and ANS function. This process helps the body naturally recover from Long COVID by reducing inflammation and improving vagus nerve function.

Key benefits of EAT therapy include:

• Addressing the root cause of Long COVID symptoms rather than just masking them
• Restoring balance to the ANS, beneficial for those with conditions like dysautonomia and postural orthostatic tachycardia syndrome (POTS)
• Reducing chronic inflammation, which contributes to fatigue and cognitive issues
• Enhancing respiratory function by alleviating postnasal drip and sinus inflammation
• Providing a fast, non-invasive, and safe treatment with minimal downtime

The success of EAT in Japan has paved the way for its introduction in the U.S., offering patients a potential new path to recovery. 

*COVID Institute. (2025, February 27). Groundbreaking Japanese Long COVID Treatment Now Available in the U.S. EIN Presswire. https://www.siouxlandproud.com/business/press-releases/ein-presswire/789355434/groundbreaking-japanese-long-covid-treatment-now-available-in-the-u-s/ 

Responsum Health closely vets all sources to ensure that we always provide you with high-quality, reliable information. We do not, however, endorse or recommend any specific providers, treatments, or products, and the use of a given source does not imply an endorsement of any provider, treatment, medication, or procedure discussed within.